Recent price moves and performance snapshot
Integra LifeSciences Holdings (IART) has drawn attention after a sharp move, with the stock up about 29% over the past week and roughly 45% over the past month from its recent levels.
See our latest analysis for Integra LifeSciences Holdings.
That surge sits against a mixed backdrop, with a 90 day share price return of 20.43% and a 3 year total shareholder return decline of 72.66%, suggesting recent momentum is rebuilding after a tough stretch.
If this kind of rebound catches your eye, it can be a useful moment to scan for other potential ideas using our healthcare focused screener for 35 healthcare AI stocks
With Integra LifeSciences trading at US$13.56, showing an intrinsic discount of 55.53% and sitting about 26.60% below analyst targets, you have to ask whether this is a genuine value opportunity or whether the market has already incorporated expectations about future growth.
Most Popular Narrative: 45.8% Undervalued
Against the last close at $13.56, the most followed narrative anchors on a fair value of $25.00, implying a sizeable valuation gap to its own estimate.
Analysts broadly agree that Integra's Compliance Master Plan and supply chain upgrades will stabilize operations and restore revenue; however, this may actually drive a structural step change in cost efficiency and supply reliability, leading to gross margin and earnings expansion well beyond conservative estimates as operational bottlenecks are permanently resolved across legacy and newly acquired sites.
Curious what sits behind that confidence in a higher fair value? The narrative leans on a sharp profit swing, steady revenue build, and a richer future earnings multiple. The exact path, timing and scale are all spelled out there, not in the recent share price.
Result: Fair Value of $25.00 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you also need to weigh ongoing quality and regulatory challenges, as well as reliance on a relatively narrow product set, which could pressure margins and limit the bullish case.
Find out about the key risks to this Integra LifeSciences Holdings narrative.
Next Steps
Given the mix of optimism and concern in this story, it makes sense to review the key facts yourself and decide quickly where you stand using our breakdown of 3 key rewards and 1 important warning sign
Looking for more investment ideas?
Do not stop at a single stock. Use the Simply Wall St screener to quickly surface fresh opportunities that fit your style before the market moves on.
- Target potential mispricing by scanning a focused set of 51 high quality undervalued stocks that combine quality traits with room for a better market view.
- Prioritize resilience by filtering for 71 resilient stocks with low risk scores that aim to keep balance sheets and risk profiles front and center.
- Spot potential early movers by checking a screener containing 23 high quality undiscovered gems before they attract wider attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com